Slashdot

News for nerds, stuff that matters

Microsoft Says October Updates Didn't Actually Fix VPN Issues

joshuark shares a report from BleepingComputer: Microsoft says it mistakenly flagged a bug causing Always On VPN connection issues as fixed in the October 2026 Windows 11 cumulative updates. Always On VPN replaced the legacy DirectAccess technology and supports domain-joined, non-domain-joined, and Microsoft Entra ID-joined devices running Windows 10, Windows 11, and Windows Server. It runs in the background and establishes secure tunnels back to the user's corporate network whenever their device connects to the internet.

Microsoft first acknowledged the issue in a service alert sent to IT administrators in late September, saying it was triggered on systems running Windows 11 24H2 and later after installing the September 2026 security updates when the initial Always On VPN connection failed (e.g., when using automatic protocol selection with IKEv2 and SSTP). "When automatic protocol selection or protocol fallback was configured, affected VPN connections could remain stuck in a Connecting state or fail to connect after an initial connection attempt failed," it said. "In some cases, subsequent connection attempts could display the error, 'The specified port is already in use.'"

After releasing the October 2026 Patch Tuesday Windows 11 cumulative updates, Microsoft marked the bug as resolved, but in a Tuesday update it said the issues weren't actually addressed and that a fix would ship later. "This disclosure was mistakenly updated to Resolved status on October 13, 2026. We have returned its status to Mitigated," it said in a service alert sent to IT admins. "A resolution for this issue is planned to be included in an update to be released in the coming weeks. We apologize for any inconvenience or confusion." While Microsoft continues working on a permanent solution, it shared a temporary fix that requires affected customers to choose one of two VPN tunneling protocols to work around the issue.

The Browser Company Retires Its Arc Browser, Pushes Users to Dia

The Browser Company is shutting down its Arc browser on December 22 and encouraging users to migrate to Dia, its newer AI-powered browser for Apple Silicon Macs and Windows 11 PCs. Thurrott reports: In the message explaining why it was sunsetting Arc, The Browser Company explained that maintaining two separate browsers was difficult to justify, especially from a security perspective. "Dia was built from the ground up to meet today's security standards, so that's where our engineering and security teams will focus moving forward," the company wrote.

The retirement of Arc will be gradual: While nothing changes for existing Arc users, it's no longer possible to create new Arc accounts as of today. On November 23, tab sync, Browse for Me, and other AI features will be disabled on the iOS and Android versions of Arc. Lastly, the desktop version of Arc will stop working on December 22, and Arc accounts will be deactivated.

Moderna Shares Plunge After Leak of Cancer Vaccine Data

Moderna shares plunged as much as 25% after partial clinical trial data leaked for its personalized cancer vaccine developed with Merck, despite the full results showing promising outcomes for melanoma patients. Analysts attribute the selloff largely to inflated investor expectations rather than disappointing clinical results. CNBC reports: The personalized vaccine, known as intismeran autogene, paired with Merck's immunotherapy Keytruda reduced the risk of recurrence or death in certain melanoma patients by 42% compared with Keytruda alone. The data also showed the shot along with Keytruda reduced the risk of cancer spreading to distant parts of the body or death by 38%, compared with just the immunotherapy. The companies say about 82% of patients who received the personalized cancer vaccine alongside Keytruda were alive without their melanoma returning at two years, compared with 70% of those who received Keytruda alone.

[...] Investors see the targeted vaccine as a possible breakthrough treatment, with the potential to be used in other forms of cancer in the future. It could also offer Moderna a critical additional commercial product in its pipeline, following vaccines for Covid-19, the flu and respiratory syncytial virus. "We assert this relative reduction in recurrence/death is clinically meaningful," said BMO Capital Markets analyst Evan Seigerman. "Such a reaction likely reflects inflated expectations into the full data release, rather than a true indictment on the efficacy of the combo therapy."

UBS analysts said "this is overall a strong data set" and gives more confidence in upcoming studies of the vaccine in kidney and bladder cancers. They added the stock reaction may be due more to massive expectations than disappointing data.